Incyte Reports Positive Results from Phase II Clinical Trial of Oral JAK1 Inhibitor
October 03, 2013 at 06:03 AM EDT
Incyte Corporation (NASDAQ: INCY ) announced results from a 28-day, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 50 patients with chronic plaque psoriasis for its proprietary oral
